Virashiv 600mg Tablet

• Treatment of HIV infection

Virashiv 600mg Tablet is a strong anti-HIV medicine that may show certain adverse while manageable impact on the body during the treatment. As these effects resolve on their own without any special medical attention. However, if you ever experience serious or unusual side effects contact your healthcare professional immediately.

Some common side effects include:

• Nausea
• Diarrhea
• Rash
• Decreased white blood cell count (neutrophils)
• Vomiting
• Abdominal pain
• Allergic reaction
• Fatigue
• Increased lipase in the blood
• Headache
• Insomnia (difficulty in sleeping)
• Depression
• Dizziness
• Abnormal dreams
• Nasopharyngitis (inflammation of the throat and nasal passages)
• Upper respiratory tract infection
• Anxiety
• Sinus inflammation

• The dosage and duration of the Virashiv 600mg Tablet are decided by the doctor based on the severity of the infection and other health factors. Take this tablet on an empty stomach for better results. Before starting this medicine, please inform your doctor about your medical history.
• If you experience any signs and symptoms while eating this medication that are not manageable, do not ignore those symptoms because they may lead to a higher risk.​
  

• Virashiv 600mg Tablet is an anti-HIV medicine which is a combination of antiretrovirals medicines such as Emtricitabine (200mg), Tenofovir disoproxil fumarate (300mg), and Efavirenz (600mg).
• They function by preventing the human immunodeficiency virus from multiplying, which reduces the infection's level in your body. Additionally, they raise the number of CD4 cells in your blood, which are white blood cells that fight infection.​
  

• ENCORE1 Study Group. (2015). Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. The Lancet Infectious Diseases, 15(7), 793-802. https://pubmed.ncbi.nlm.nih.gov/25877963/
• Venter, W. D., Sokhela, S., Simmons, B., Moorhouse, M., Fairlie, L., Mashabane, N., ... & Hill, A. (2020). Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. The lancet HIV, 7(10), e666-e676. https://pubmed.ncbi.nlm.nih.gov/33010240/
• Deeks, E. D., & Perry, C. M. (2010). Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (Atripla®) A Review of its Use in the Management of HIV Infection. Drugs, 70(17), 2315-2338. https://pubmed.ncbi.nlm.nih.gov/17266471/
• ENCORE1 Study Group. (2014). Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial. The Lancet, 383(9927), 1474-1482.https://pubmed.ncbi.nlm.nih.gov/24522178/
• Goicoechea, M., & Best, B. (2007). Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all?. Expert Opinion on Pharmacotherapy, 8(3), 371-382.
• Frampton, J. E., & Croom, K. F. (2006). Efavirenz/emtricitabine/tenofovir disoproxil fumarate: triple combination tablet. Drugs, 66(11), 1501-1512.